{"denoms":[{"counts":[{"groupId":"BG000","value":"17"}],"units":"Participants"}],"groups":[{"description":"Participants with relapsed or refractory waldenstrom's macroglobulinemia received ibrutinib 420 milligrams (mg) (3\\*140 mg capsules) orally once daily from Day 1 of Week 1 until disease progression, unacceptable toxicity, whichever occurs first.","id":"BG000","title":"Ibrutinib 420 mg"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"6.95","value":"64.1"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"10"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"17"}],"title":"Asian/Not Hispanic or Latino"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}]}